New hope for lung cancer patients with brain spread after standard treatment fails
NCT ID NCT05805631
First seen Mar 28, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests a new treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis) and has stopped responding to the drug osimertinib. The treatment combines a chemotherapy drug (pemetrexed) given directly into the spinal fluid with a targeted therapy pill (tyrosine kinase inhibitor). The goal is to control the disease and improve survival. About 23 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Chest Medicine, Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan, 11217, Taiwan
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.